SS Innovations International Inc. (NASDAQ: SSII), a developer of innovative surgical robotic technologies, announced record second-quarter 2026 revenue of $13.9 million, a 39.4% increase from $10.0 million in the same period last year. The company's first-half revenue reached $25.0 million, a 65.6% jump from $15.1 million in the first half of 2025, underscoring sustained demand for its SSi Mantra surgical robotic system.
The company's gross profit for the second quarter increased 20.0% to $7.1 million, though gross margin declined to 50.9% from 59.1% in the year-earlier quarter. For the first half, gross profit rose 77.5% to $12.4 million, with improved gross margin compared to the prior-year period. These financial results reflect the company's expanding commercial footprint and operational scaling.
Installations of the SSi Mantra system rose 30.4% to 30 systems during the quarter, bringing the total installed base to 224 systems across 12 countries. Cumulative surgeries performed on the platform reached 12,272, demonstrating growing clinical adoption. The company highlighted that system installations remain the primary commercial growth driver, while its telesurgery achievements are extending the clinical profile of SSi Mantra.
A key focus for investors is the regulatory pathway in major markets. SS Innovations is targeting U.S. Food and Drug Administration (FDA) clearance by the first quarter of 2027 and European CE marking by the end of 2026. These milestones could act as significant catalysts, opening access to the world's largest healthcare markets and potentially accelerating revenue growth.
The company's telesurgery capabilities, which allow surgeons to operate remotely, are enhancing the value proposition of the SSi Mantra platform. This technology could expand surgical access in underserved regions and position SS Innovations as a leader in remote surgical solutions. As the installed base grows, recurring revenue from service contracts and instrument sales may provide additional stability.
The record revenue and strategic progress come amid a competitive landscape where robotic surgery is rapidly evolving. SS Innovations' focus on affordability and versatility could differentiate it from established players. The company's expansion into multiple countries indicates growing international acceptance, and regulatory approvals in the U.S. and Europe would likely bolster its competitive position.
For the broader medical device industry, the continued growth of SSi Mantra underscores the increasing adoption of robotic-assisted surgery, which offers benefits such as precision, reduced patient trauma, and shorter recovery times. As more systems are installed, the potential for improved patient outcomes and cost efficiencies in healthcare systems becomes more tangible.
Investors and industry observers will be watching for further updates on regulatory submissions and new market entries. The company's ability to maintain its growth trajectory while managing margins will be critical. With a strong first half and a clear roadmap, SS Innovations appears well-positioned to build on its momentum.
